arrow
R

Richard Adams

cardiff university
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database

评估西妥昔单抗治疗转移性结直肠癌的纵向毒性和不良事件:一项来自ARCAD数据库中1,302例患者的合并分析

2026-08-240
PRE
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms

转移性结直肠癌随机试验中基于ARCAD衍生外部对照臂的总体生存期可重复性

2026-08-220
PRE
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK

西地尼布联合每周多西他赛或奥拉帕利与每周多西他赛对比治疗晚期或复发性子宫内膜癌(COPELIA):一项在英国进行的多中心、开放标签、随机、II期临床试验

2026-06-010
OAAI
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine

ABC-12:探索度伐利尤单抗(MEDI4736)联合顺铂/吉西他滨一线治疗晚期胆道癌患者中的微生物组

2025-07-290
PRE
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial

标准剂量与减量放化疗在肛管癌中的比较(PLATO-ACT4):一项II期随机对照试验的短期结果

2025-05-040
OAAI
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative

促进欧洲胃肠道癌症大型跨国学术临床研究:ENGIC(欧洲胃肠道癌症网络)倡议

2025-05-010
OA
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

MEK1/2抑制剂比尼美替尼与MET抑制剂克唑替尼在RAS突变型晚期结直肠癌 (汞) 患者中的Ia/b期研究

2025-04-100
OAAI
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
2024-10-240
OAAI
Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database

肝转移、KRAS突变和种族在结直肠癌患者中的预后价值:一项基于ARCAD数据库的第三线安慰剂对照试验的合并分析

2024-09-010
PRE
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation
2024-03-013
PRE
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
2024-02-240
OA